Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioscience Animal Health PCLBKK:BIS -0.88%83 Return-on-Tangible-Equity is 8.91% as of Mar. 2026, which is 19% below its 10-year median of 10.96. GuruFocus rates BKK:BIS with a GF Score™ of 83/100 and a GF Value™ of ฿2.86 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,881 Consumer Packaged Goods companies, Bioscience Animal Health PCL ranks worse than 61.51% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bioscience Animal Health PCL's annualized net income for the quarter that ended in Mar. 2026 was ฿70 Mil. Bioscience Animal Health PCL's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ฿787 Mil. Therefore, Bioscience Animal Health PCL's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 8.91%.
The historical rank and industry rank for Bioscience Animal Health PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:BIS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.18 Med: 10.96 Max: 33.17
Current: 4.7
During the past 9 years, Bioscience Animal Health PCL's highest Return-on-Tangible-Equity was 33.17%. The lowest was 4.18%. And the median was 10.96%.
BKK:BIS's Return-on-Tangible-Equity is ranked worse than 61.51% of 1881
companies
in the Consumer Packaged Goods industry
Industry Median: 7.78
vs BKK:BIS: 4.70
Bioscience Animal Health PCL (BKK:BIS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bioscience Animal Health PCL Return-on-Tangible-Equity Related Terms
Bioscience Animal Health PCL Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioscience Animal Health PCL Return-on-Tangible-Equity Chart
BKK:BIS vs KHC, GIS: Return-on-Tangible-Equity Comparison
For the Packaged Foods subindustry, Bioscience Animal Health PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioscience Animal Health PCL Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioscience Animal Health PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bioscience Animal Health PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.91% mean?
Bioscience Animal Health PCL (BKK:BIS) has a Return-on-Tangible-Equity of 8.91% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioscience Animal Health PCL and its competitors. This is 19% below median its historical median of 10.96. Over the past decade, Bioscience Animal Health PCL's Return-on-Tangible-Equity has ranged from 4.18 to 33.17. According to the industry distribution chart, Bioscience Animal Health PCL ranks #1157 out of 1881 companies in the Consumer Packaged Goods industry, placing it in the top 61.5%.
Is Bioscience Animal Health PCL's Return-on-Tangible-Equity too high?
Bioscience Animal Health PCL's current Return-on-Tangible-Equity of 8.91% is 19% below median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 4.18 to a high of 33.17. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 7.78. Bioscience Animal Health PCL's value of 8.91% is 14.5% above this industry median. Based on the distribution chart, Bioscience Animal Health PCL ranks #1157 out of 1881 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Bioscience Animal Health PCL has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioscience Animal Health PCL's Return-on-Tangible-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Bioscience Animal Health PCL ranks #1157 out of 1881 companies for Return-on-Tangible-Equity. This places Bioscience Animal Health PCL in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.78. Bioscience Animal Health PCL's value of 8.91% is 14.5% above this benchmark. Historically, Bioscience Animal Health PCL's own Return-on-Tangible-Equity has ranged from 4.18 to 33.17 over the past decade. While the company's 10-year median is 10.96 vs. the industry median of 7.78, Bioscience Animal Health PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.78, based on 1,881 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioscience Animal Health PCL's current Return-on-Tangible-Equity of 8.91% is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioscience Animal Health PCL and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioscience Animal Health PCL's current Return-on-Tangible-Equity is 8.91%, which is 19% below median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioscience Animal Health PCL stock overvalued right now?
Based on GuruFocus' analysis, Bioscience Animal Health PCL (BKK:BIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.86, compared to a current price of ฿2.24 — trading 21.7% below its estimated fair value. The current Return-on-Tangible-Equity is 8.91%, which is 19% below median its 10-year median of 10.96 and 14.5% above the Consumer Packaged Goods industry median of 7.78. Bioscience Animal Health PCL's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bioscience Animal Health PCL (BKK:BIS), the current Return-on-Tangible-Equity is 8.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioscience Animal Health PCL (BKK:BIS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioscience Animal Health PCL stock appears to be undervalued.
The current stock price of ฿2.24 is trading 21.7% below its estimated GF Value™ of ฿2.86.
GuruFocus considers Bioscience Animal Health PCL to be Modestly Undervalued.
Key valuation signals for BKK:BIS:
Return-on-Tangible-Equity: 8.91% (19% below median its 10-year median of 10.96)
GF Value™: ฿2.86 vs. price of ฿2.24 (21.7% below fair value)
Industry Position: 14.5% above the Consumer Packaged Goods median (#1157 of 1881)
No single metric tells the full story. See the BKK:BIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioscience Animal Health PCL along with its subsidiaries is engaged in the manufacturing, import and distribution of pharmaceutical supplies, medical devices, equipment and products for livestock and companion animals (pets). Geographically, the company generates revenue from Thailand, and also has presence in other countries.
83GF Score
Get the complete analysis for BKK:BIS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIS has been successfully added to your 
